NFKB1 and adult T-cell leukemia/lymphoma: Finally, bortezomib, a protease inhibitor with NF-kB inhibitory activity, has shown some promise in relapsed or refractory aggressive adult T-Cell leukemia, which shows frequent gain-of-function alterations in the TCR/NF-kB signaling pathway due to an altered PLGC1 gene [82].